AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20870337 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity cognitive therapy without nicotine replacement therapy (NRT)
Number of subjects: 1843
Study 20870337 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention (control group)
Number of subjects: 1843
Study 20870337 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow up in clinics (NRT group)
Number of subjects: 1843
Study 20870337 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow up via telephone sessions (NRT group)
Number of subjects: 1843
Study 19615208 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin administration (100 ml 20% human albumin daily for 3 days)
Number of subjects: 127
Study 19615208 — intervention group
Group type: COMPARATOR
Intervention: Saline administration (100 ml saline daily for 3 days)
Number of subjects: 127
Study 19615208 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 127
Study 16960162 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean oil (SO)
Number of subjects: 30
Study 16960162 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-saturated fatty acid soybean oil (LoSFA-SO)
Number of subjects: 30
Study 16960162 — intervention group
Group type: EXPERIMENTAL
Intervention: High-oleic acid soybean oil (HiOleic-SO)
Number of subjects: 30
Study 16960162 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-alpha-linolenic acid soybean oil (LoALA-SO)
Number of subjects: 30
Study 16960162 — intervention group
Group type: COMPARATOR
Intervention: Partially hydrogenated soybean oil (Hydrog-SO)
Number of subjects: 30
Study 16960162 — intervention group
Group type: EXPERIMENTAL
Intervention: Unhydrogenated soybean oils (SO, LoSFA-SO, HiOleic-SO, LoALA-SO)
Number of subjects: 30
Study 15175800 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban (ARG) at doses of 1.0, 2.0, or 3.0 microg/kg/min
Number of subjects: 39
Study 15175800 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban (ARG) at doses of 1.0, 2.0, or 3.0 microg/kg/min combined with VKA
Number of subjects: 39
Study 15175800 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban (ARG) combined with VKA
Number of subjects: 39
Study 15175800 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban (ARG) at doses up to 2 microg/kg/min
Number of subjects: 39
Study 15175800 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecarin Clotting Time (ECT)
Number of subjects: 39
Study 15635852 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity training (Group A)
Number of subjects: 22
Study 15635852 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity training (Group B)
Number of subjects: 22
Study 9468763 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-fat group
Number of subjects: 220
Study 9468763 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 220
Study 9468763 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 220
Study 7945491 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CYC)
Number of subjects: 122
Study 7945491 — intervention group
Group type: COMPARATOR
Intervention: High-dose prednisone
Number of subjects: 122
Study 7945491 — intervention group
Group type: COMPARATOR
Intervention: Immunosuppressive other than cyclophosphamide
Number of subjects: 122
Study 7945491 — intervention group
Group type: COMPARATOR
Intervention: D-penicillamine
Number of subjects: 122
Study 7945491 — intervention group
Group type: COMPARATOR
Intervention: No drug
Number of subjects: 122
Study 3556129 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 mEq of Slow-K given as 8 mEq/tablet tid
Number of subjects: 20
Study 3556129 — intervention group
Group type: COMPARATOR
Intervention: 30 mEq of K-Tab given as 10 mEq/tablet tid
Number of subjects: 20
Study 30241488 — intervention group
Group type: EXPERIMENTAL
Intervention: VivaSight™‐SL tube (VST)
Number of subjects: 54
Study 30241488 — intervention group
Group type: COMPARATOR
Intervention: Conventional intubation under direct laryngoscopy (DL)
Number of subjects: 54
Study 30241488 — intervention group
Group type: EXPERIMENTAL
Intervention: VST
Number of subjects: 54
Study 30241488 — intervention group
Group type: COMPARATOR
Intervention: DL
Number of subjects: 54
Study 27333950 — intervention group
Group type: EXPERIMENTAL
Intervention: Loving-Kindness Meditation (LKM)
Number of subjects: 809
Study 27333950 — intervention group
Group type: COMPARATOR
Intervention: Light Exercise (LE)
Number of subjects: 809
Study 27333950 — intervention group
Group type: EXPERIMENTAL
Intervention: Both courses (LKM and LE)
Number of subjects: 809
Study 24225560 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (ARG; 0.075 g·kg‐1 body mass)
Number of subjects: 14
Study 24225560 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 14
Study 24225560 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (ARG)
Number of subjects: 14
Study 23643522 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (40 mg/day)
Number of subjects: 48
Study 23643522 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc + ALA supplementation (2 g/day flaxseed oil)
Number of subjects: 48
Study 23643522 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 48
Study 23643522 — intervention group
Group type: COMPARATOR
Intervention: IL-6
Number of subjects: 48
Study 23643522 — intervention group
Group type: COMPARATOR
Intervention: CRP
Number of subjects: 48
Study 23643522 — intervention group
Group type: COMPARATOR
Intervention: TNF-α
Number of subjects: 48
Study 21336433 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased intake of fruits and vegetables (six servings each per day) during the first postoperative month
Number of subjects: 60
Study 21336433 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 60
Study 17983841 — intervention group
Group type: EXPERIMENTAL
Intervention: PEMF stimulation after surgery (PEMF group, 163 patients)
Number of subjects: 323
Study 17983841 — intervention group
Group type: COMPARATOR
Intervention: Control group (160 patients)
Number of subjects: 323
Study 16537857 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial hyperresponsiveness (BHR) determined by methacholine challenge test with a provocative concentration producing a 20% fall in FEV(1) < or = 8 mg/mL.
Number of subjects: 3454
Study 16537857 — intervention group
Group type: EXPERIMENTAL
Intervention: Definite asthma defined as BHR present with any asthma symptom within the past 12 months or demonstrated reversible airflow obstruction.
Number of subjects: 3454
Study 16537857 — intervention group
Group type: EXPERIMENTAL
Intervention: Current diagnosed asthma defined as previous physician‐diagnosed asthma and any asthma symptom within the past 12 months or currently receiving asthma medication.
Number of subjects: 3454
Study 14678209 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch testing with hydroxycitronellal plus sodium lauryl sulfate (SLS)
Number of subjects: 20
Study 14678209 — intervention group
Group type: COMPARATOR
Intervention: Patch testing with hydroxycitronellal alone
Number of subjects: 20
Study 10802474 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic solution of neomycin and polymyxin B
Number of subjects: 50
Study 10802474 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% providone‐iodine solution
Number of subjects: 50
Study 10802474 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate solution
Number of subjects: 50
Study 10802474 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated dropped grafts)
Number of subjects: 50
Study 8829861 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA
Number of subjects: 26
Study 8829861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 8829861 — intervention group
Group type: COMPARATOR
Intervention: Reference puncture (no anaesthesia)
Number of subjects: 26
Study 1735845 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic surfactant (Exosurf Neonatal)
Number of subjects: 2
Study 1735845 — intervention group
Group type: COMPARATOR
Intervention: Air placebo
Number of subjects: 2
Study 6428917 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliquidone (Glurenorm)
Number of subjects: 20
Study 6428917 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 20
Study 30724455 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin treatment
Number of subjects: 48
Study 27733650 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic exercises only (Group 1)
Number of subjects: 33
Study 27733650 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiology taping on the affected side with inhibition technique plus therapeutic exercises (Group 2)
Number of subjects: 33
Study 27733650 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiology taping on the unaffected side with facilitation technique and on the affected side with inhibition technique plus therapeutic exercises (Group 3)
Number of subjects: 33
Study 25943466 — intervention group
Group type: EXPERIMENTAL
Intervention: Home BP/PP variability parameters
Number of subjects: 150
Study 25943466 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency (LF) power of beat‐to‐beat BP/PP variability
Number of subjects: 150
Study 25943466 — intervention group
Group type: EXPERIMENTAL
Intervention: PP variability parameters
Number of subjects: 150
Study 25943466 — intervention group
Group type: EXPERIMENTAL
Intervention: Home HR variability parameters
Number of subjects: 150
Study 25943466 — intervention group
Group type: EXPERIMENTAL
Intervention: 24‐h hour‐to‐hour HR variability
Number of subjects: 150
Study 24400953 — intervention group
Group type: COMPARATOR
Intervention: 4 mg intravenous dexamethasone
Number of subjects: 30
Study 24400953 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg oral dexamethasone
Number of subjects: 30
Study 24400953 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of 6 mg oral vs. 4 mg intravenous dexamethasone
Number of subjects: 30
Study 22928400 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary program (MP), n = 86
Number of subjects: 173
Study 22928400 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC), n = 87
Number of subjects: 173
Study 19002481 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A injection (2-5 IU in 0.2-0.5 ml of saline)
Number of subjects: 63
Study 19002481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 17729055 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium powder 3.5 gr t.i.d.
Number of subjects: 141
Study 17729055 — intervention group
Group type: COMPARATOR
Intervention: Guar gum 3.5 gr t.i.d.
Number of subjects: 141
Study 17729055 — intervention group
Group type: COMPARATOR
Intervention: Standard diet
Number of subjects: 141
Study 15535166 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with orbital prefrontal cortex damage
Number of subjects: 0
Study 15535166 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study 10770543 — intervention group
Group type: EXPERIMENTAL
Intervention: RTV/SQV
Number of subjects: 208
Study 10770543 — intervention group
Group type: COMPARATOR
Intervention: RTV/SQV/D4T
Number of subjects: 208
Study 10770543 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified treatment
Number of subjects: 208
Study 10770543 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 208
Study 9307249 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral high-frequency stimulation of the ventral intermedius nucleus of the thalamus
Number of subjects: 53
Study 8340603 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human alpha 2A interferon (6 million units three times per week for 6 months)
Number of subjects: 40
Study 8340603 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 40
Study 8340603 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human alpha 2A interferon
Number of subjects: 40
Study 3552659 — intervention group
Group type: EXPERIMENTAL
Intervention: B-mode ultrasound
Number of subjects: 42
Study 3552659 — intervention group
Group type: EXPERIMENTAL
Intervention: Halved skinfold
Number of subjects: 42
Study 3552659 — intervention group
Group type: EXPERIMENTAL
Intervention: A-mode ultrasound
Number of subjects: 42
Study 3552659 — intervention group
Group type: EXPERIMENTAL
Intervention: Skinfold calipers
Number of subjects: 42
Study 3552659 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between protocols for men
Number of subjects: 42
Study 3552659 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between protocols for women
Number of subjects: 42
Study 30285891 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment for IBS
Number of subjects: 600
Study 30285891 — intervention group
Group type: COMPARATOR
Intervention: Western medicine treatment for IBS
Number of subjects: 600
Study 25862026 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-gripping mesh repair
Number of subjects: 507
Study 25862026 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein repair with suture fixation
Number of subjects: 507
Study 27845635 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months of daily isoniazid preventive therapy (IPT)
Number of subjects: 82
Study 27845635 — intervention group
Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 82
Study 22440275 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF Trap‐Eye 2 mg
Number of subjects: 189
Study 22440275 — intervention group
Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 189
Study 20551734 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based intervention protocol for emotional support
Number of subjects: 40
Study 20551734 — intervention group
Group type: COMPARATOR
Intervention: Usual standard of care
Number of subjects: 40
Study 18700371 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading protocol (loaded within 24 hours of surgery)
Number of subjects: 30
Study 18700371 — intervention group
Group type: COMPARATOR
Intervention: Delayed loading protocol (connected to a healing abutment and restored after 3 to 4 months)
Number of subjects: 30
Study 18700371 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading protocol
Number of subjects: 30
Study 18700371 — intervention group
Group type: COMPARATOR
Intervention: Delayed loading protocol
Number of subjects: 30
Study 15970844 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose hCG (200 IU intramuscular injection daily) after 100 mg CC
Number of subjects: 67
Study 15970844 — intervention group
Group type: COMPARATOR
Intervention: 150 mg CC
Number of subjects: 67
Study 12890761 — intervention group
Group type: EXPERIMENTAL
Intervention: BDNF val66met genotype (met carriers)
Number of subjects: 0
Study 12890761 — intervention group
Group type: COMPARATOR
Intervention: BDNF val66met genotype (val homozygotes)
Number of subjects: 0
Study 12890761 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction between BDNF val66met genotype and hippocampal response during encoding
Number of subjects: 0
Study 11026416 — intervention group
Group type: EXPERIMENTAL
Intervention: Drawing of the sun on the bottom of customers' checks
Number of subjects: 0
Study 11026416 — intervention group
Group type: COMPARATOR
Intervention: No drawing on the bottom of customers' checks
Number of subjects: 0
Study 9004107 — intervention group
Group type: COMPARATOR
Intervention: Trandolapril 2 mg and placebo
Number of subjects: 23
Study 9004107 — intervention group
Group type: COMPARATOR
Intervention: Trandolapril 2 mg and indomethacin
Number of subjects: 23
Study 9004107 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin and placebo
Number of subjects: 23
Study 9004107 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo and placebo
Number of subjects: 23
Study 9004107 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril 2 mg
Number of subjects: 23
Study 9004107 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 23
Study 1857525 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin with blood transfusions (group 1)
Number of subjects: 24
Study 1857525 — intervention group
Group type: COMPARATOR
Intervention: Blood transfusions alone (group 2)
Number of subjects: 24
Study 6863470 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 3810
Study 6863470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3810
Study 31076823 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-based left atrial appendage closure
Number of subjects: 0
Study 31076823 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing randomized studies
Number of subjects: 0
Study 31076823 — intervention group
Group type: EXPERIMENTAL
Intervention: CLOSURE AF trial
Number of subjects: 0
Study 29095516 — intervention group
Group type: EXPERIMENTAL
Intervention: Vesair balloon placement
Number of subjects: 221
Study 29095516 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 221
Study 26037274 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% silver diammine fluoride (SDF) solution applied every 12 months
Number of subjects: 304
Study 26037274 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% silver diammine fluoride (SDF) solution applied three times at weekly intervals at baseline
Number of subjects: 304
Study 26037274 — intervention group
Group type: COMPARATOR
Intervention: 5% sodium fluoride (NaF) varnish applied three times at weekly intervals at baseline
Number of subjects: 304
Study 24930428 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (2000 units)
Number of subjects: 104
Study 24930428 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (4000 units)
Number of subjects: 104
Study 22328464 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 404
Study 22328464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study 20627222 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 2305
Study 20627222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2305
Study 17586783 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10 or 20 mg per day)
Number of subjects: 405
Study 17586783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 405
Study 17586783 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 405
Study 16238765 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge planning intervention
Number of subjects: 126
Study 16238765 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 126
Study 12127180 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment of insomnia
Number of subjects: 130
Study 12127180 — intervention group
Group type: EXPERIMENTAL
Intervention: SDB treatment (either nasal CPAP or nasal turbinates)
Number of subjects: 130
Study 12127180 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment of insomnia (10 sleep hygiene recommendations)
Number of subjects: 130
Study 12127180 — intervention group
Group type: EXPERIMENTAL
Intervention: SDB treatment (nasal CPAP or nasal turbinates)
Number of subjects: 130
Study 10388231 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphocyte predominance (LP) pattern observed in lymph nodes of breast and stomach carcinomas; significant association with stage and grade of disease in breast carcinoma.
Number of subjects: 64
Study 10388231 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological patterns classified as lymphocyte predominance (LP), germinal centre predominance (GCP), lymphocyte depletion (LD), and unstimulated (U).
Number of subjects: 64
Study 8569816 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutrimazole 1% solution, applied once daily for 4 weeks
Number of subjects: 40
Study 8569816 — intervention group
Group type: COMPARATOR
Intervention: Bifonazole 1% solution, applied once daily for 4 weeks
Number of subjects: 40
Study 2357865 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine hydrochloride 0.5 mg/hr
Number of subjects: 57
Study 2357865 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine hydrochloride 1 mg/hr
Number of subjects: 57
Study 2357865 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine hydrochloride 2 mg/hr
Number of subjects: 57
Study 2357865 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine hydrochloride 4 mg/hr
Number of subjects: 57
Study 2357865 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine hydrochloride 5 mg/hr
Number of subjects: 57
Study 2357865 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine hydrochloride 8 mg/hr
Number of subjects: 57
Study 2357865 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine hydrochloride 2 mg/hr (severe hypertension)
Number of subjects: 57
Study 2357865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 6274571 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH (10 i.u./day)
Number of subjects: 0
Study 6274571 — intervention group
Group type: COMPARATOR
Intervention: Sham infusions
Number of subjects: 0
Study 6274571 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone infusions
Number of subjects: 0
Study 6274571 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol or indomethacin (additional treatment)
Number of subjects: 0
Study 30979038 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum PS128 (PS128)
Number of subjects: 0
Study 30979038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29251954 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based affect-focused psychodynamic therapy (IPDT) for 10 weeks
Number of subjects: 72
Study 29251954 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 72
Study 27454410 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated Integrated Mood Management (FIMM); 5 therapist-facilitated psychoeducation sessions.
Number of subjects: 121
Study 27454410 — intervention group
Group type: COMPARATOR
Intervention: Manualized Integrated Mood Management (MIMM); self-administered psychoeducation.
Number of subjects: 121
Study 27454410 — intervention group
Group type: EXPERIMENTAL
Intervention: Both FIMM and MIMM interventions.
Number of subjects: 121